Albireo Announces Positive Results From A Study With A3309 In Patients With Chronic Constipation
Albireo announced that additional clinical data will be reported from a recent study assessing the safety, tolerability and efficacy of A3309 in patients with chronic constipation. A3309 is a first-in-class investigational compound for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC)…
This entry was posted on Friday, April 30th, 2010 at 2:00 am and is filed under Irritable Bowel Syndrome. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.